Exercise for Ameliorating Chemotherapy Cardiotoxicity
NCT06595316 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2024-09-19
Summary
Chemotherapy is a common treatment for breast cancer but can damage the heart and blood vessels. Exercise, such as cycling, may stop chemotherapy from damaging the heart and blood vessels. Before the effects of exercise on the heart and blood vessels can be fully determined in a large trial, a small trial must first be carried out to assess if exercise can be included safely and practically during chemotherapy treatment.
This study is designed so that a group of breast cancer patients will exercise during their chemotherapy treatment, whilst another group does not exercise. Participants will be breast cancer patients from the Queen's Centre for Oncology and Haematology at Castle Hill Hospital. Suitable patients will be identified and approached by their Consultant Clinical Oncologist. If patients decide to take part, they will be randomly placed into groups ('exercise' or 'usual care') before starting chemotherapy. The exercise group will exercise for 50-60 minutes 2days/week in the Cardiac Rehabilitation Gym at Castle Hill Hospital during their chemotherapy treatment. Exercise will be supervised, consisting of repeated 5-minute bouts of high intensity cycling plus strength training. The usual care group will be given their normal chemotherapy only (no exercise). Both groups will take part in tests before they begin chemotherapy treatment. Tests assess heart and blood vessel health, fitness, strength, fatigue, and quality of life. The same tests will happen again during the intervention, after the intervention and 3-months later. Participants will also have to complete questionnaires to give their opinion of the study. The main point of the study is to determine if the exercise and tests are received well by patients, if recruitment is good, and if patients comply/adhere. This will inform a larger study which will assess if exercise maintains heart and vessel health during chemotherapy treatment.
Conditions
Interventions
- OTHER
-
Exercise intervention group
Exercise will consist of two supervised sessions per week. Starting with vital signs monitoring (blood pressure, temperature, blood oxygen levels, heart rate). The aerobic component consists of a 5-minute warm-up, followed by 3 bouts of 4-minute cycling at an intensity of 60-65% HRR, with 2-minute active recovery periods in between and a 5-minute cool down. The goal is to increase up to an intensity of around 80%-85% HRR by weeks 16 to 18. Intensity will be monitored with The Borg Rating Scale of Perceived Exertion (RPE). The resistance component will consist of upper body and lower body exercises (door frame rows, wall push-ups, glute bridges, triceps lifts and squat to calf rise) starting on week one with a set of 12 repetitions of each exercise, with 2-minute recovery in between exercises aiming to increase the number of sets and reducing the number of repetitions.
Sponsors & Collaborators
-
Hull University Teaching Hospitals NHS Trust
collaborator OTHER_GOV -
University of Hull
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-10-15
- Primary Completion
- 2025-12-01
- Completion
- 2025-12-01
More Related Trials
-
Exercise Program in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
NCT03280836 ·Status: COMPLETED ·Phase: NA
-
High-Intensity Interval Training for Stage I-III Breast Cancer Patients
NCT02454777 ·Status: TERMINATED ·Phase: NA
-
Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity
NCT05036252 ·Status: ACTIVE_NOT_RECRUITING
-
Cardioprotective Effect of Acute Exercise in Breast Cancer Patients
NCT05467111 ·Status: RECRUITING ·Phase: NA
-
Investigating Paclitaxel Toxicity in Breast Cancer: the Roles of Physical Activity and Body Composition.
NCT06387901 ·Status: RECRUITING
-
Adaptive Training Exercise Programs for Improving Cardiorespiratory Fitness After Breast Cancer Treatment, The ACTIVATE Trial
NCT04667481 ·Status: COMPLETED ·Phase: NA
-
CARdiac Function Evaluation in Breast Cancer Patients
NCT03266809 ·Status: COMPLETED
-
EXercise Influence on Taxane Side Effects (EXIT) Study
NCT02473861 ·Status: COMPLETED ·Phase: NA
-
Genetics and Heart Health After Cancer Therapy
NCT03510689 ·Status: COMPLETED
-
Exercise to Prevent AnthraCycline-based Cardio-Toxicity Study 2.0 (EXACT2)
NCT03748550 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Cardiac Rehabilitation Program on the Prevention of Cardiotoxicity in Breast Cancer Patients Undergoing Treatment With Anthracyclines and/or Trastuzumab
NCT06881940 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Early Detection and Prediction of Chemotherapy Induced Cardiac Toxicity in Breast Cancer Patients
NCT00806507 ·Status: COMPLETED
-
STOP Heart Disease in Breast Cancer Survivors Trial
NCT02674204 ·Status: TERMINATED ·Phase: PHASE2
-
AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer
NCT00310089 ·Status: COMPLETED ·Phase: NA
-
MIBG Scintigraphy and Strain Echocardiography in the Detection of Subclinical Cardiovascular Effects One Year After (Neo)Adjuvant Breast Cancer Treatment With Docetaxel, Doxorubicin and Cyclophosphamide (TAC): a Pilot Study
NCT01246856 ·Status: UNKNOWN
-
High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Metastatic or Recurrent Breast Cancer
NCT00003032 ·Status: COMPLETED ·Phase: PHASE3
-
Combination Chemotherapy in Treating Women With Breast Cancer
NCT00047099 ·Status: COMPLETED ·Phase: PHASE3
-
Doxorubicin or Epirubicin and Cyclophosphamide in Treating Older Women With Invasive Breast Cancer
NCT00516425 ·Status: UNKNOWN ·Phase: PHASE3
-
Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients
NCT05732051 ·Status: RECRUITING ·Phase: PHASE2
-
Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer
NCT00005970 ·Status: COMPLETED ·Phase: PHASE3
-
Combination Chemotherapy in Treating Women With Resected Breast Cancer
NCT00033683 ·Status: UNKNOWN ·Phase: PHASE2
-
Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer
NCT00024102 ·Status: COMPLETED ·Phase: PHASE3
-
Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer
NCT00003680 ·Status: UNKNOWN ·Phase: PHASE3
-
Characterization and Kinetic of Chemotherapy-induced Cardiovascular Toxicity in Breast Cancer
NCT05803889 ·Status: TERMINATED
-
A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer
NCT03705429 ·Status: COMPLETED ·Phase: PHASE3